<DOC>
	<DOCNO>NCT00003967</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness topotecan plus etoposide treating patient recurrent ovarian cancer , peritoneal cancer , fallopian tube cancer .</brief_summary>
	<brief_title>Topotecan Plus Etoposide Treating Patients With Recurrent Ovarian , Peritoneal , Fallopian Tube Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose sequential prolonged topotecan prolong etoposide second line therapy patient recurrent ovarian epithelial , peritoneal , tubal cancer . II . Determine nature degree toxicity treatment regimen patient population . III . Evaluate response rate time disease progression patient . OUTLINE : This dose escalation study . Patients receive oral topotecan daily day 1-5 oral etoposide daily day 8-10 . Courses repeat every 28 day absence disease progression unacceptable side effect . Patients achieve partial complete response stable disease continue treatment least 4-6 course . Cohorts 3-6 patient receive topotecan etoposide increase number day maximum tolerate dose ( MTD ) determine . The MTD define dose great 1 6 patient experience dose limit toxicity . Patients follow every 3 month death . PROJECTED ACCRUAL : A total 24 patient accrue study within 12 month .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial , peritoneal , tubal cancer Epithelial cell type Serous adenocarcinoma Endometrioid adenocarcinoma Mucinous adenocarcinoma Undifferentiated carcinoma Clear cell adenocarcinoma Mixed epithelial carcinoma Transitional cell Malignant Brenner 's tumor Adenocarcinoma otherwise specify Measurable evaluable disease No brain leptomeningeal metastases No symptomatic bowel involvement ovarian cancer Not eligible high priority GOG phase II III study PATIENT CHARACTERISTICS : Age : 18 Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time normal SGOT/SGPT/GGT great 3 time normal Alkaline phosphatase great 3 time normal No acute hepatitis Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance great 50 mL/min Other : No septicemia severe infection Body surface area least 1 m2 Adequate intestinal function ( i.e. , require IV hydration nutritional support ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month prior study No malignancy within past 5 year except curatively treat skin cancer No severe medical problem would prevent compliance No condition GI tract would affect GI absorption motility No severe gastrointestinal bleeding PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : No prior topotecan , camptothecin analog , etoposide At least 1 prior cisplatin/paclitaxel base regimen At least 3 week since prior chemotherapy recover No 2 prior cytotoxic chemotherapy regimens No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy cancer Radiotherapy : At least 3 week since prior radiotherapy 10 % bone marrow recover No concurrent radiotherapy Surgery : Not specify Other : At least 28 day 5 half life since prior investigational drug ( include cytotoxic drug ) No concurrent metoclopramide cisapride maintain gastric motility empty No chronic H2 antagonist , proton pump inhibitor , antacid gastritis , gastroesophageal reflux disease , gastric duodenal ulcer Intermittent antacid allow , antacid 6 hour prior 90 minute topotecan</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>ovarian undifferentiated adenocarcinoma</keyword>
	<keyword>ovarian mixed epithelial carcinoma</keyword>
	<keyword>ovarian serous cystadenocarcinoma</keyword>
	<keyword>ovarian mucinous cystadenocarcinoma</keyword>
	<keyword>ovarian endometrioid adenocarcinoma</keyword>
	<keyword>ovarian clear cell cystadenocarcinoma</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
	<keyword>Brenner tumor</keyword>
</DOC>